BerGenBio ASA announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the company's selective AXL inhibitor bemcentinib in combination with MSD's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback